Finance

Beta
Lists
CBIO:NASDAQ
Crescent Biopharma Inc
$17.36
-0.80%
(-0.14) 1D
Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
$17.41
High
$17.80
Low
$16.92
Mkt. cap
479.20M
Avg. vol.
257.31K
Volume
175.78K
52-wk high
$27.41
52-wk low
$8.72
EPS
-$12.25
Beta
1.16
Shares outstanding
27.57M
No. of employees
55
Open
$17.41
High
$17.80
Low
$16.92
Mkt. cap
479.20M
Avg. vol.
257.31K
Volume
175.78K
52-wk high
$27.41
52-wk low
$8.72
EPS
-$12.25
Beta
1.16
Shares outstanding
27.57M
No. of employees
55
News stories
From sources across the web
About Crescent Biopharma Inc
CEO-
Employees55
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitecrescentbiopharma.com
Analyst Ratings
Based on 7 analysts giving stock ratings to CBIO in the past 3 months
Strong Buy
Buy
6
Hold
1
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current $17.36
$35.00 (+101.61%)
Average
$31.00 (+78.57%)
Lowest
$27.00 (+55.53%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
$35.00
+101.6%
06/23/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$30.00
+72.8%
06/23/2026
Robert Driscoll
Wedbush
Buy
Maintained
$27.00
+55.5%
06/01/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Downgraded
-
-
06/01/2026
Bradley Canino
Guggenheim
Buy
Maintained
$35.00
+101.6%
04/29/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$28.00
+61.3%
04/30/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
10.84M
1.04M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.08M
20.35M
95.03M
17.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.95M
5.54M
7.31M
7.86M
Operating expense
21.03M
25.88M
102.34M
25.77M
Total operating expenses
21.03M
25.88M
102.34M
25.77M
Operating income
-21.03M
-25.88M
-91.49M
-24.73M
Other non operating income
-
-
-
-
EBT including unusual items
-21.79M
-24.61M
-90.40M
-23.28M
EBT excluding unusual items
-21.79M
-24.61M
-90.40M
-23.28M
Income tax expense
-
-
2.00M
-
Effective tax rate
-
-
-2.21%
-
Other operating expenses
-
-
-
-
Net income
-21.79M
-24.61M
-92.40M
-23.28M
Net profit margin
-
-
-852.06%
-2,240.90%
Earnings per share
-3.72
-1.37
-4.92
-0.70
Interest and investment income
313.00K
1.28M
1.10M
1.45M
Interest expense
-1.07M
-
-
-
Net interest expenses
-760.00K
1.28M
1.10M
1.45M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.03M
-25.86M
-91.44M
-24.66M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer